Pre- & Post-vaccine Trends in Pneumococcal Serotypes & Antimicrobial Resistance Patterns

Overview

Journal Indian J Med Res

Specialty General Medicine

Date 2024 Dec 5

PMID 39632638

Authors

Sreeram Chandra Murthy Peela

Sujatha Sistla

Geetha Nagaraj

Vandana Govindan

Ravi Kumar Lingegowda Kadahalli

Affiliations

Soon will be listed here.

Abstract

Background & objectives The Pneumococcal vaccines were introduced under the Universal Immunization Programme (UIP) in 2021 in India. Drawing from the collective experience of various nations, it is anticipated that there will be a substantial shift in serotype patterns following the introduction of this vaccine. The available data is limited to years until 2018 when the vaccine was introduced in only five States. The present study was carried out to estimate the changes in serotypes and antimicrobial resistance patterns pre- and post-vaccine introduction from a tertiary care centre. Methods All isolates from various clinical specimens in the pre-vaccine era (January 2015-July 2021, except for 2019) and post-vaccine era (August 2021- March 2023) were included. Antimicrobial susceptibility was tested using disc diffusion or VITEK2, and serotyping was performed using the Quellung test (post-vaccine introduction) or sequential multiplex PCR (pre-vaccine introduction). The Chi-square or Fisher exact test was used to identify associations between antimicrobial resistance and serotypes. The z-test for proportions was used to identify significant changes in serotype frequencies between the pre- and post-vaccine era; P<0.05 was considered as the level of significance. Results Overall, the resistance rates increased for most of the antibiotics in the post-vaccine era, and there was no significant increase in the non-vaccine serotypes. The proportion of serotypes 19F and 15B/C increased, and serotypes 23F and 14 reduced in the post-vaccine era. The majority of the 19F and 19A isolates (89.7% and 80%, respectively) were multidrug resistant in the post-vaccine era. Interpretation & conclusions Introducing pneumococcal vaccination reduced the burden of many vaccine serotypes, while the burden of non-vaccine serotypes slightly increased. Most of the vaccine serotypes (like 19F and 19A) that persisted in the post-vaccine era were drug resistant.

References

Lochen A, Croucher N, Anderson R . Divergent serotype replacement trends and increasing diversity in pneumococcal disease in high income settings reduce the benefit of expanding vaccine valency. Sci Rep. 2020; 10(1):18977. PMC: 7643077. DOI: 10.1038/s41598-020-75691-5. View

Lo S, Mellor K, Cohen R, Alonso A, Belman S, Kumar N . Emergence of a multidrug-resistant and virulent Streptococcus pneumoniae lineage mediates serotype replacement after PCV13: an international whole-genome sequencing study. Lancet Microbe. 2022; 3(10):e735-e743. PMC: 9519462. DOI: 10.1016/S2666-5247(22)00158-6. View

Rudolph K, Parkinson A, Black C, Mayer L . Evaluation of polymerase chain reaction for diagnosis of pneumococcal pneumonia. J Clin Microbiol. 1993; 31(10):2661-6. PMC: 265966. DOI: 10.1128/jcm.31.10.2661-2666.1993. View

Wasserman M, Chapman R, Lapidot R, Sutton K, Dillon-Murphy D, Patel S . Twenty-Year Public Health Impact of 7- and 13-Valent Pneumococcal Conjugate Vaccines in US Children. Emerg Infect Dis. 2021; 27(6):1627-1636. PMC: 8153862. DOI: 10.3201/eid2706.204238. View

Ahmed S, Pondo T, Xing W, McGee L, Farley M, Schaffner W . Early Impact of 13-Valent Pneumococcal Conjugate Vaccine Use on Invasive Pneumococcal Disease Among Adults With and Without Underlying Medical Conditions-United States. Clin Infect Dis. 2019; 70(12):2484-2492. DOI: 10.1093/cid/ciz739. View

Oliveira G, Oliveira M, Miyaji E, Rodrigues T . Pneumococcal Vaccines: Past Findings, Present Work, and Future Strategies. Vaccines (Basel). 2021; 9(11). PMC: 8620834. DOI: 10.3390/vaccines9111338. View

Bar-Zeev N, Swarthout T, Everett D, Alaerts M, Msefula J, Brown C . Impact and effectiveness of 13-valent pneumococcal conjugate vaccine on population incidence of vaccine and non-vaccine serotype invasive pneumococcal disease in Blantyre, Malawi, 2006-18: prospective observational time-series and case-control.... Lancet Glob Health. 2021; 9(7):e989-e998. PMC: 8220129. DOI: 10.1016/S2214-109X(21)00165-0. View

Park H, Lee S, Yoon J, Shin J, Shin H, Kook J . Identification of the cpsA gene as a specific marker for the discrimination of Streptococcus pneumoniae from viridans group streptococci. J Med Microbiol. 2010; 59(Pt 10):1146-1152. DOI: 10.1099/jmm.0.017798-0. View

Ganaie F, Saad J, Lo S, McGee L, van Tonder A, Hawkins P . Novel pneumococcal capsule type 33E results from the inactivation of glycosyltransferase WciE in vaccine type 33F. J Biol Chem. 2023; 299(9):105085. PMC: 10462825. DOI: 10.1016/j.jbc.2023.105085. View

10.

Kim C, Song J, Choi S, Song K, Choe P, Beom Park W . Serotype Distribution and Antimicrobial Susceptibilities of Invasive Streptococcus pneumoniae Isolates from Adults in Korea from 1997 to 2012. J Korean Med Sci. 2016; 31(5):715-23. PMC: 4835596. DOI: 10.3346/jkms.2016.31.5.715. View

11.

Jin P, Xiao M, Kong F, Oftadeh S, Zhou F, Liu C . Simple, accurate, serotype-specific PCR assay to differentiate Streptococcus pneumoniae serotypes 6A, 6B, and 6C. J Clin Microbiol. 2009; 47(8):2470-4. PMC: 2725661. DOI: 10.1128/JCM.00484-09. View

12.

Feikin D, Kagucia E, Loo J, Link-Gelles R, Puhan M, Cherian T . Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites. PLoS Med. 2013; 10(9):e1001517. PMC: 3782411. DOI: 10.1371/journal.pmed.1001517. View

13.

Weinberger D, Malley R, Lipsitch M . Serotype replacement in disease after pneumococcal vaccination. Lancet. 2011; 378(9807):1962-73. PMC: 3256741. DOI: 10.1016/S0140-6736(10)62225-8. View

14.

See K . Pneumococcal Vaccination in Adults: A Narrative Review of Considerations for Individualized Decision-Making. Vaccines (Basel). 2023; 11(5). PMC: 10223523. DOI: 10.3390/vaccines11050908. View

15.

Nagaraj G, Govindan V, Ganaie F, Venkatesha V, Hawkins P, Gladstone R . genomic datasets from an Indian population describing pre-vaccine evolutionary epidemiology using a whole genome sequencing approach. Microb Genom. 2021; 7(9). PMC: 8715438. DOI: 10.1099/mgen.0.000645. View

16.

Ono T, Watanabe M, Hashimoto K, Kume Y, Chishiki M, Okabe H . Serotypes and Antibiotic Resistance of before and after the Introduction of the 13-Valent Pneumococcal Conjugate Vaccine for Adults and Children in a Rural Area in Japan. Pathogens. 2023; 12(3). PMC: 10056172. DOI: 10.3390/pathogens12030493. View